The Master of Science (M.Sc.)in Medical Informatics (MMI) at European Campus Rottal-Inn (ECRI) in Pfarrkirchen - a branch of the Deggendorf University of Applied Sciences (THD - Technische Hochschule Deggendorf) in Bavaria, Germany - is accepting applications for entry in October 2019.

A leading mental health service is using the digital mental health platform developed by SilverCloud Health to support a confidential NHS service for GPs in England. London-based Efficacy is offering doctors using the GP Health Service access to the SilverCloud platform, on which there are more than 30 programmes, to improve mental health and related conditions.

The Doctrina Academy is a new service, developed by Doctrina, a video e-learning platform that reaches over 1,000,000 healthcare professionals (HCPs) from around the globe, helping them to switch from volume-based to value-based continuing education. The company was founded in 2013 and has since made it easier for HCPs to decide on the right treatment and medicine for the right patient at the right time.

Propel@YH has announced the six start-ups to participate in its inaugural digital health accelerator programme, aimed at navigating the complex healthcare landscape and building an NHS-relevant business case. The Leeds-based programme is commissioned by the Yorkshire & Humber AHSN (Academic Health Science Network) in partnership with mHabitat, an NHS-owned specialist and expert in the application of digital to health and care.

The parent company to Patientrack - which provides technology to NHS hospitals to alert staff when patients are at risk of harm - has entered into a reseller agreement withhealthcare software provider Better by Marand tohelp hospitals tackle medication errors.

Sensyne Health plc (LSE: SENS), the British clinical AI technology company, and Bayer, the life sciences company, announce that Bayer has become Sensyne Health's preferred pharmaceutical partner to work together on the development of a national linked patient data capability. Bayer joins Microsoft, EY, JP Morgan, and Peel Hunt in this consortium.

AstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).